List View

By /

Clear

Displaying 2,851 - 2,875 of 2,995

What is New After ASCO and ESMO 2024 in Colon and Rectal Cancer Management?

What is New After ASCO and ESMO 2024 in Colon and Rectal Cancer Management?

HCC and Pancreatic Cancer: Novel Therapies after ASCO and ESMO 2024

HCC and Pancreatic Cancer: Novel Therapies after ASCO and ESMO 2024

Esophageal and Gastric Carcinomas: Moving the Bar Up after ESMO 2024

Esophageal and Gastric Carcinomas: Moving the Bar Up after ESMO 2024

Colorectal Cancer Genomic Profiling, Tumor-Informed or Tumor Naïve. Primetime and Utility?

Colorectal Cancer Genomic Profiling, Tumor-Informed or Tumor Naïve. Primetime and Utility?

Antibody Drug Conjugates for HER2 Negative Breast Cancer: Advancing Breast Cancer Management

Antibody Drug Conjugates for HER2 Negative Breast Cancer: Advancing Breast Cancer Management

Sequencing of Therapies for Multiple Myeloma

Sequencing of Therapies for Multiple Myeloma

Treatment of Patients Progressing after BTKi and BCL2i

Treatment of Patients Progressing after BTKi and BCL2i

Novel Therapies for Aggressive Non-Hodgkin Lymphomas

Novel Therapies for Aggressive Non-Hodgkin Lymphomas

Will Biosimilars Reduce Financial Toxicity of Cancer Therapy

Will Biosimilars Reduce Financial Toxicity of Cancer Therapy

Hepatocellular Carcinoma: Are We Finally Making Progress?

Hepatocellular Carcinoma: Are We Finally Making Progress?

Esophageal Carcinoma – Finally Something Practice Changing

Esophageal Carcinoma – Finally Something Practice Changing

Artificial Intelligence in Cancer Therapeutics: Fact or Fiction?

Artificial Intelligence in Cancer Therapeutics: Fact or Fiction?

New Developments in Small Cell Lung Cancer

New Developments in Small Cell Lung Cancer

Targeted Therapy and Resistance, New Agents are Coming

Targeted Therapy and Resistance, New Agents are Coming

Antibody Drug Conjugates in Lung Cancer

Antibody Drug Conjugates in Lung Cancer

Perioperative Immunotherapy in NSCLC

Perioperative Immunotherapy in NSCLC

RCC in 2025: What’s New for the Practicing Oncologist?

RCC in 2025: What’s New for the Practicing Oncologist?

Prostate and Bladder Cancers: What Have we Learned Over the Past Year?

Prostate and Bladder Cancers: What Have we Learned Over the Past Year?

Incorporating Immunotherapy in the Management of Cervical Cancer

Incorporating Immunotherapy in the Management of Cervical Cancer

Molecular Classification in Endometrial Cancer: A Real-World Approach to Staging and Treatment

Molecular Classification in Endometrial Cancer: A Real-World Approach to Staging and Treatment

Immunotherapy in Ovarian Cancer: Is There a Role, and for Whom?

Immunotherapy in Ovarian Cancer: Is There a Role, and for Whom?

Major Endocrine and Targeted Therapy Advances In the Treatment of HR+/HER2- Breast Cancer

Major Endocrine and Targeted Therapy Advances In the Treatment of HR+/HER2- Breast Cancer

Advances in the Treatment of HER2+ Breast Cancer

Advances in the Treatment of HER2+ Breast Cancer

New Directions In Chemotherapy and Immunotherapy for HR+ Breast Cancer

New Directions In Chemotherapy and Immunotherapy for HR+ Breast Cancer

Immunotherapy and Optimal Chemotherapy for Early Stage TNBC: When and in Whom?

Immunotherapy and Optimal Chemotherapy for Early Stage TNBC: When and in Whom?